When it comes to #germanium, here is why #ROCK matters.
🇨🇳 controls 85% of the world's supply.
🇪🇺 needs its own resource.
#Rock is well positioned to deliver.
@HMRCcustomers Hi, I'm wanting to setup a payment plan for the tax I owe Jan 31st 2024. It tells me I already have one when trying to setup online. I did have one but this finished June 28th 2023. Can you advise please. Kind regards
@CartlandDavid Not perfectly matched and we don't expect it to work, this has to be a joke. The world's gone mad and this lady needs locking away with this video clip on repeat!!!
Decided to take several more tranches in @ShieldTx this AM, on the pullback. Evidently some hefty profit taking, following the 50% gain over four sessions last week; but I think the move north resumes shortly.
#STX is in the process of ramping up sales of its lead medicine, ACCRUFeR, the first and only FDA-approved oral therapy for iron deficiency. The company has a commercial partnership with NASDAQ-listed Viatris, the global healthcare business, in which each entity has recruited a 50-person sales team to target the 12,000+ highest prescribers.
As Thursday's update revealed, growth in prescriptions in the US is increasing at a rate of knots. Q2 subscription were 173% higher than the same period in 2022, and 50% higher than just the previous quarter, Q1 2023. In June alone, increase in total prescriptions over May was 30%.
The handful of brokers covering this stock suggest that this run-rate will be sufficient for STX to generate in the region of £25m in revenue this year.
However, the three brokers' (finnCap, Hardman, Edison) average revenue and EBITDA forecasts for next year are £75.3m and -£1.0m, followed by £127.6m and £32.9m in 2025.
I would also point out that the blended average of their fair valuations is £396.5m, or 55.6p per share. That's 508% higher than STX's current SP of 9.15p.
Whilst we should take sell-side research with a large fistful of salt (I should know more than most, I used to be one!) - the consistency of (up-to-date) valuation targets suggests that STX should indeed be sitting substantially higher than its current mkt cap of only £65m.
[It's also important to note that the market opportunity for iron deficiency, just in the US, could be as much as $2.3bn. STX has patent protection on ACCRUFeR across multiple territories up until 2035.]
Cash on hand of $13.6m (at 30 June) is, in mgmt's view, sufficient to see @ShieldTx through to cash flow positive in H2 next year.
My own initial SP target for this breakout trade is the mid-teens. Will review position if / when achieved.
@sophielouisecc So people have had 3/4 vaccinations and they're worried about an unvaccinated child 🤔 Surely the vaccinated are fully protected! I'm confused 😕